On our screens:Stocks with no debt
Is the price fair?
What REGN's price assumes
Regeneron Pharmaceuticals trades at 20.0× earnings against 31.5× for the median Biotechnology name, cheaper than its own group.
20.0
Trailing P/E · Biotechnology median 31.5 · cheaper than the typical name in its group
- Price / sales
- 5.57
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.9%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +3.5%
Growth the price implies · The price pays for +3.5% free cash flow growth a year for a decade; the business has delivered −3.3% a year over the last three.
Details›
- Price / book2026-Q1
- 2.64
- EV / EBIT2026-Q1
- 22.6
- EV / sales2026-Q1
- 5.50
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $3.76B
- Market capitalisation
- $63.9B
- 3-year revenue growth
- +7.0%
- 3-year free cash flow growth
- −3.3%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $651.72 |
| Its own P/E history, median | $822.18 |
| Its own P/E history, upper quartile | $1,000.55 |
| 52-week range | $553.32 – $852.16 |
| Today | $810.46 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
The closest names by size in the same industry